comprehensive -WSS

comprehensive

author：comprehensive 2025-10-01 15:29:53 - browse：621

Principal Deputy FDA Commissioner Janet Woodcock Stefani Reynolds/The New York Times via AP

WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the Food and Drug Administration after helping steer the agency through an historic period of medical advances during nearly four decades in key leadership positions, she confirmed to STAT Thursday.

Woodcock, a doctor with a chemistry degree, joined FDA in 1986 at its biologics center, where she oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis. In 1994, she was named director of the drug center, where she played a key role in guiding some of the most impactful changes to the regulation of medicine, according to Trump administration FDA Commissioner Scott Gottlieb.

Woodcock envisioned that antibody drugs would become a backbone of therapy and created a more predictable regulatory path for their review and approval, Gottlieb said. She presided over a major expansion and modernization of the generic drug program, standardizing reviews in a way that allowed the industry to become safer and more robust, and crafted the reform of over-the-counter drug reviews.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Wikipedia

WSS

A new drug could help frostbite victims avoid its ravages

New CMS data security rules will hurt Medicare, Medicaid research

MD Anderson's Padmanee Sharma responds to research credit suit

Medicare inequities exacerbate Puerto Rico’s health disparities

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

WATCH: Why do our ears pop?

focus

comprehensive

focus

Apple is now the first public company to be valued at $3 trillion

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Hepatitis C has a cure — but many Americans still lack access to it

Abridge raises $150m as clinical notes automation market heats up

Medicare proposal to cover medical devices draws a mixed reaction

Ukraine seeks to reclaim its role as a hub for clinical trials

Activists slam private health insurers over coverage restrictions

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

ChatGPT in medicine: STAT answers readers' burning questions

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

entertainment

Secretariat’s lessons for human medicine

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

New CMS data security rules will hurt Medicare, Medicaid research

NIH study of ME/CFS points to clear biological hallmarks

Ukraine seeks to reclaim its role as a hub for clinical trials

leisure time

Wikipedia

Wikipedia

focus